Adagio Medical Reports Third Quarter 2026 Results
Key Highlights
- ➤Net income $17.8 million, versus $10.1 million loss, driven by $23.0 million noncash gain
- ➤Cash and equivalents $3.1 million, down from $17.1 million at December 31, 2025
- ➤Board initiated formal strategic-alternatives process focused on maximizing shareholder value
- ➤vCLAS Ultra IDE sub-study treated first patient, beginning multi-site enrollment
- ➤Adagio completed one-for-thirty reverse split to regain Nasdaq minimum bid compliance
Expert Statements
Todd Usen, Chief Executive Officer of Adagio Medical
“The third quarter was defined by progress in the clinical and regulatory programs that we believe are the foundation for the value of Adagio and our ULTA platform. Our PMA application for the vCLAS Ventricular Ablation System remains under FDA review, and we initiated the vCLAS Ultra IDE study, which builds on the FULCRUM-VT results with a faster, more maneuverable next-generation catheter. We were also pleased to see ULTA featured in several podium presentations at the recent VT Symposium, reinforcing the clinical differentiation of a purpose-built, all-endocardial approach to VT”
Todd Usen, Chief Executive Officer of Adagio Medical
“As the Board’s review of strategic alternatives continues, we have aligned our cost structure around these prioritized programs and remain focused on maximizing value for our shareholders.”
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the third quarter ended September 30, 2026.
* Ultra-Low temperature ablation (“ULTA”) featured in four podium presentations at the VT Symposium 2026 held October 9-10 in New York, with topics spanning clinical experience, comparative preclinical research and insights from FULCRUM-VT, with particular physician interest centered on the next-generation vCLAS Ultra catheter’s handling, streamlined workflow, and ability to create time efficient deep wide footprint lesions with predictable dimensions
Get started
Create a free account to read the full story.
